Between June 1988 and July 1989, 10 patients affected by transitional cell carcinoma of the bladder (Ta-T1, N0, M0; G1-2) were enrolled in this clinical trial. A dose escalating scheme from 18 x 103 to 18 x 106 IU/m2/day was used in subgroups of 3 patients each. Two five-day cycles of rIL-2, with a 48-hour interruption in between, were administered. Continuous intra-arterial infusion was performed through a 5 Fr angiographic catheter in the hypogastric artery. Transurethral resection of the bladder tumor was performed 4 days after the end of the 2nd cycle. Two complete and two partial responses were observed out of 10 treated patients. In 6 cases, no modification of the tumor was observed. Immunological monitoring of peripheral blood lymphocytes demonstrated activation of T lymphocyte subpopulations and increase of NK, LAK and ADCC cytotoxicity in some patients.
|Translated title of the contribution||Neoadjuvant immunotherapy with interleukin-2 in patients with early-stage bladder carcinoma. Clinical and immunological aspects|
|Number of pages||6|
|Journal||Acta Urologica Italica|
|Issue number||6 SUPPL. 1|
|Publication status||Published - 1990|
ASJC Scopus subject areas